A dry formulation of a vaccine comprises a live attenuated virus, 30% to 80% (w/w) of a non-reducing oligosaccharide, 5% to 40% (w/w) of an amino acid stabilizer, 2% to 20% (w/w) of a protein stabilizer, and a buffer having a pH of 6.0 to 8.0. The amino acid stabilizer is arginine and wherein said dry formulation is prepared as a cake, prepared on a membrane or filter, dried as a powder, by freeze-drying in beads, by spray drying, or by spray freeze drying. A method of vaccinating a non-human animal against a virus selected from the group consisting of distemper virus, adenovirus, parainfluenza virus, parvovirus, and any combination thereof, comprising mixing the above described dry formulation with a pharmaceutically acceptable carrier to form a liquid vaccine and then administering the liquid vaccine to the non-human animal. A vaccine comprises the above described dry formulation combined with a dry formulation comprising a live attenuated parvovirus, 10% to 80% (w/w) of a sugar alcohol, 10% to 70% (w/w) of a bulking stabilizer, 4% to 50% (w/w) of a protein stabilizer, a buffer having a pH of 6.8 to 8.0 and a liquid pharmaceutically acceptable carrier.
